📋 Key Information Summary
- The coagulation cascade comprises intrinsic (contact-activated), extrinsic (tissue factor–triggered), and common pathways; modern anticoagulants target specific factors (IIa, Xa) rather than the entire cascade.
- Warfarin inhibits vitamin K–dependent factors (II, VII, IX, X) and requires INR monitoring with a target range of 2.0–3.0 for most indications and 2.5–3.5 for mechanical heart valves.
- Warfarin has a narrow therapeutic index, extensive drug–food interactions, and a slow onset/offset; it remains the preferred agent for mechanical heart valves and antiphospholipid syndrome in Australia.
- Warfarin over-anticoagulation is managed with vitamin K₁ (phytomenadione) 1–2.5 mg PO for INR 4.5–8.0 without bleeding; IV prothrombin complex concentrate (PCC) for life-threatening haemorrhage.
- UFH is the anticoagulant of choice for cardiopulmonary bypass, ECMO, and haemodialysis; it requires aPTT or anti-Xa monitoring and is immediately reversible with protamine sulfate.
- LMWH (enoxaparin, dalteparin) provides predictable pharmacokinetics, is weight-based dosed, and requires no routine monitoring in most patients — anti-Xa levels guide dosing in obesity, renal impairment, and pregnancy.
- DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) are first-line for non-valvular atrial fibrillation and VTE treatment/prophylaxis in Australia, supported by PBS listing and Phase III trial data.
- Dabigatran (direct thrombin inhibitor) is the only DOAC with a specific reversal agent available in Australia — idarucizumab (Praxbind®), PBS Authority Required.
- Andexanet alfa (Ondexxya®) is PBS-listed for apixaban and rivaroxaban reversal in life-threatening haemorrhage; PCC 4-factor (Octaplex®) is an alternative non-specific reversal strategy.
- DOACs are contraindicated in mechanical heart valves and antiphospholipid syndrome; dose reduction criteria vary by agent and must be applied per TGA-approved indications to avoid under-dosing.
- Renal function (eGFR/creatinine clearance) is critical for DOAC dosing: dabigatran is contraindicated if CrCl <30 mL/min; dose adjustments apply to all DOACs with declining renal function.
- Aboriginal and Torres Strait Islander peoples experience higher rates of AF and VTE with lower anticoagulant utilisation; culturally safe prescribing, medication access, and monitoring support are essential.
Introduction & Australian Epidemiology
Anticoagulant therapy is fundamental to the management of venous thromboembolism (VTE), atrial fibrillation (AF), mechanical heart valves, and various hypercoagulable states. The main classes — vitamin K antagonists (warfarin), heparins (UFH and LMWH), and direct oral anticoagulants (DOACs) — differ markedly in their mechanisms of action, monitoring requirements, drug interactions, and reversal strategies. Understanding these differences is essential for safe prescribing in Australian clinical practice.
In Australia, VTE affects approximately 14,000–20,000 people annually, with an age-adjusted incidence of 83 per 100,000 population. Atrial fibrillation prevalence increases with age, affecting 4–5% of Australians over 60 years and approximately 10% of those aged ≥80 years. The 2023 AIHW National Hospital Morbidity Database reports over 60,000 hospitalisations with a primary or secondary diagnosis of AF and more than 30,000 with VTE per year.
The shift from warfarin to DOACs has been transformative. Australian PBS dispensing data (2023) demonstrate that apixaban and rivaroxaban now account for approximately 75% of anticoagulant prescriptions for non-valvular AF. However, warfarin retains important niches — mechanical prosthetic heart valves, antiphospholipid syndrome, and severe renal impairment — and UFH/LMWH remain critical for acute inpatient management, bridging therapy, and pregnancy.
Prescribing safety: Anticoagulant-related bleeding accounts for approximately 4,000 Australian hospital admissions annually. The ACSQHC has prioritised anticoagulant safety as a National Safety and Quality Health Service (NSQHS) Standard. Always confirm indication, dose, renal function, and drug interactions before prescribing.
Coagulation Cascade Overview
The coagulation cascade is a series of enzymatic reactions involving serine proteases (clotting factors) that ultimately convert fibrinogen to a stable fibrin clot. The cascade is traditionally divided into three pathways, though in vivo haemostasis is best understood through the cell-based model of coagulation.
Classical Three-Pathway Model
| Pathway | Trigger | Key Factors | Laboratory Test |
|---|---|---|---|
| Intrinsic (contact) | Contact with negatively charged surface (collagen, glass in vitro) | XII → XI → IX → VIII | aPTT (activated partial thromboplastin time) |
| Extrinsic (tissue factor) | Tissue factor (TF) exposure from damaged vessel wall | TF + VII | PT / INR |
| Common | Convergence of intrinsic and extrinsic pathways | X → V → II (prothrombin) → I (fibrinogen) → XIII | Both PT and aPTT |
Cell-Based Model (Current Understanding)
The cell-based model describes three overlapping phases occurring on cell surfaces:
- Initiation: Tissue factor exposed on subendothelial cells binds factor VIIa, generating small amounts of thrombin (IIa) and activating factors V, VIII, IX, and X.
- Amplification: Trace thrombin activates platelets and cofactors (V, VIII, XI) on the platelet surface, setting the stage for large-scale thrombin generation.
- Propagation: The tenase complex (IXa/VIIIa) and prothrombinase complex (Xa/Va) on activated platelet surfaces generate a "thrombin burst," cleaving fibrinogen to fibrin and activating factor XIII for clot stabilisation.
Natural Anticoagulant Mechanisms
| Mechanism | Target | Clinical Relevance |
|---|---|---|
| Antithrombin (AT) | Inhibits thrombin (IIa) and factor Xa | Heparin cofactor; AT deficiency → thrombophilia |
| Protein C / Protein S | Inactivate factors Va and VIIIa | Protein C/S deficiency → warfarin-induced skin necrosis risk |
| Tissue factor pathway inhibitor (TFPI) | Inhibits TF–VIIa–Xa complex | Limiting initiation phase |
Fibrinolysis
The fibrinolytic system dissolves clots through plasmin, generated from plasminogen by tissue plasminogen activator (tPA). Alpha-2-antiplasmin and plasminogen activator inhibitor-1 (PAI-1) regulate fibrinolysis. Pharmacological fibrinolysis (e.g., alteplase) is used in acute ST-elevation myocardial infarction, massive pulmonary embolism, and acute ischaemic stroke.
Practical pearl: The aPTT is prolonged by heparin (monitors UFH); the INR is prolonged by warfarin (monitors VKA). DOACs prolong either or both tests variably — these are not reliable monitoring tools for DOAC therapy.
Warfarin: Mechanism, Monitoring & Reversal
Mechanism of Action
Warfarin inhibits vitamin K epoxide reductase (VKORC1), preventing recycling of vitamin K to its reduced (hydroquinone) form. This blocks the gamma-carboxylation of vitamin K–dependent clotting factors (II, VII, IX, X) and anticoagulant proteins (C and S), resulting in non-functional, partially carboxylated factors.
Warfarin has near-complete oral bioavailability, is highly protein-bound (>95% to albumin), and is metabolised primarily by CYP2C9 (S-warfarin, the more potent enantiomer) and CYP3A4 (R-warfarin). The CYP2C9*2 and *3 polymorphisms reduce metabolism and increase bleeding risk. The VKORC1 -1639G→A polymorphism increases warfarin sensitivity. Pharmacogenomic dosing algorithms (e.g., IWPC algorithm) exist but are not yet standard of care in Australia.
Pharmacokinetics
- Onset: Anticoagulant effect begins in 24–72 hours (dependent on factor VII t½ ~6 hours); full effect at 5–7 days (factor II t½ ~60 hours).
- Duration: Effect lasts 3–5 days after cessation.
- Absorption: Complete; peak plasma at 1–4 hours.
- Protein binding: >95% albumin.
- Metabolism: Hepatic CYP2C9 (major), CYP3A4, CYP1A2.
- Half-life: 20–60 hours (mean ~40 hours).
Australian Indications
| Indication | Target INR | Duration |
|---|---|---|
| Atrial fibrillation (valvular or mechanical valve) | 2.0–3.0 (non-valvular AF: DOACs preferred) | Long-term |
| Mechanical prosthetic heart valve | 2.5–3.5 (aortic: 2.0–3.0 if bileaflet + no risk factors) | Lifelong |
| Antiphospholipid syndrome (APS) | 2.0–3.0 (triple-positive: 3.0–4.0) | Lifelong |
| VTE treatment & secondary prophylaxis | 2.0–3.0 | 3–12 months or indefinite |
| Bioprosthetic valve (first 3 months post-op) | 2.0–3.0 | 3 months |
Dosing & Initiation
Standard initiation in Australia: 5 mg daily for most adults. Lower starting doses (2–3 mg) recommended for elderly patients (>70 years), hepatic impairment, malnutrition, heart failure, concomitant interacting medications, or CYP2C9 variant carriers.
Warfarin Sodium
Coumadin® · Marevan® · Generic · Vitamin K antagonist
Adult dose
2–10 mg PO once daily (initiate 5 mg; adjust to INR target)
Paediatric dose
0.1–0.2 mg/kg PO daily (neonates: 0.1 mg/kg); adjust to INR
Route
Oral (also available IV as warfarin sodium injection)
Renal adjustment
None required; monitor more frequently with renal impairment
Hepatic adjustment
Dose reduction required; enhanced sensitivity in liver disease
PBS status
✔ PBS General Benefit
Monitoring
- INR target: 2.0–3.0 for most indications (see table above).
- Initiation: Check INR at day 3, day 5, then daily until stable.
- Stable: INR every 4 weeks (may extend to 12 weeks in highly stable patients per RACGP guidance).
- Dose changes: Adjust by 5–20%; recheck INR in 1–2 weeks.
- Point-of-care (POC) INR: CoaguChek® devices validated for community use; ensure quality assurance programme compliance.
Drug Interactions (Key Examples)
| Interaction Type | Drugs | Mechanism |
|---|---|---|
| Potentiate (↑ INR) | Amiodarone, fluconazole, metronidazole, erythromycin, ciprofloxacin, NSAIDs, SSRIs | CYP2C9 inhibition, protein displacement, antiplatelet effect |
| Reduce effect (↓ INR) | Rifampicin, carbamazepine, phenytoin, St John's wort | CYP enzyme induction |
| Vitamin K–rich foods | Green leafy vegetables, broccoli, Brussels sprouts | Antagonise warfarin; maintain consistent intake |
Reversal Strategies
Mild
INR 4.5–8.0, No Bleeding
Withhold 1–2 doses. Consider vitamin K₁ (phytomenadione) 1–2.5 mg PO. Recheck INR in 24 hours.
Setting: Outpatient / GP
Moderate
INR >8.0, No Bleeding / Minor Bleeding
Withhold warfarin. Vitamin K₁ 2.5–5 mg PO (effect in 24–48 hrs). Recheck INR in 12–24 hours. Repeat vitamin K₁ if INR still elevated.
Setting: Hospital / ED
Severe
Life-Threatening Haemorrhage
Withhold warfarin. IV vitamin K₁ 10 mg slow IV infusion. 4-factor PCC (Octaplex®) 25–50 IU/kg IV (based on INR). Target INR <1.5 within 15 minutes. Consider fresh frozen plasma if PCC unavailable.
Setting: ICU / ED resuscitation
Vitamin K₁ (Phytomenadione)
Konakion® MM · Vitamin K antagonist reversal
Adult dose
1–2.5 mg PO (mild); 2.5–5 mg PO (moderate); 10 mg slow IV (severe)
Paediatric dose
0.5–1 mg PO; 0.1–0.2 mg/kg slow IV (neonates 0.5–1 mg)
Route
Oral (preferred); IV (slow infusion over 20 min — anaphylaxis risk)
PBS status
✔ PBS General Benefit
4-Factor Prothrombin Complex Concentrate (PCC)
Octaplex® · Factors II, VII, IX, X + Protein C & S
Adult dose
25–50 IU/kg IV (max 3,000 IU); dose based on INR and body weight
Onset
INR normalisation within 15 minutes of infusion completion
PBS status
⚠ PBS Authority Required
Warfarin-induced skin necrosis: Occurs in patients with protein C deficiency started on warfarin without prior heparin bridging. Protein C (short half-life ~8 hours) is depleted before procoagulant factors, causing a transient hypercoagulable state. Presents as painful purpuric skin lesions 2–5 days after initiation. Treat with immediate warfarin cessation, IV vitamin K₁, and heparin bridging.
Heparin (UFH & LMWH): Indications & Reversal
Mechanism of Action
Heparin is a glycosaminoglycan that potentiates antithrombin (AT) by approximately 1,000-fold. The heparin–AT complex inactivates thrombin (factor IIa) and factor Xa. UFH requires a minimum pentasaccharide chain of 18 saccharides to catalyse both anti-IIa and anti-Xa activity, while LMWH fragments (mean MW 4,500 Da) primarily catalyse anti-Xa activity with minimal anti-IIa effect.
UFH vs LMWH — Comparative Features
| Feature | Unfractionated Heparin (UFH) | Low Molecular Weight Heparin (LMWH) |
|---|---|---|
| Molecular weight | 3,000–30,000 Da (mean ~15,000) | 2,000–9,000 Da (mean ~4,500) |
| Anti-Xa:Anti-IIa ratio | 1:1 | 2:1 to 4:1 |
| Bioavailability | 30% SC (unpredictable) | 90% SC (predictable) |
| Half-life | 1–2 hours (IV) | 3–7 hours (SC) |
| Monitoring | Required — aPTT (or anti-Xa) | Not routine — anti-Xa if indicated (obesity, renal, pregnancy) |
| Reversal agent | Protamine sulfate (full neutralisation) | Protamine sulfate (~60% neutralisation of anti-Xa) |
| HIT risk | Higher (~1–5%) | Lower (~0.1–1%) |
| Renal clearance | Reticuloendothelial | Renal — dose adjust if CrCl <30 mL/min |
| Route | IV infusion or SC | SC injection |
Indications
| UFH Preferred | LMWH Preferred |
|---|---|
| Cardiopulmonary bypass | VTE prophylaxis (medical/surgical) |
| ECMO | VTE treatment (outpatient eligible) |
| Haemodialysis | Cancer-associated thrombosis |
| Acute massive PE with haemodynamic instability | Pregnancy (enoxaparin preferred) |
| Severe renal impairment (CrCl <15 mL/min) | Bridging therapy for warfarin |
| When rapid reversal anticipated | ACS (STEMI/NSTEMI — enoxaparin) |
LMWH Agents Available in Australia
Enoxaparin
Clexane® · Generic · LMWH
Prophylactic dose
40 mg SC once daily (20 mg if CrCl <30 mL/min or wt <50 kg)
Treatment dose
1 mg/kg SC BD (1 mg/kg OD if CrCl <30 mL/min)
Paediatric dose
0.75 mg/kg SC BD (<2 months); 0.5 mg/kg SC BD (≥2 months)
Renal adjustment
CrCl <30 mL/min: reduce to OD dosing; anti-Xa monitoring recommended
PBS status
✔ PBS General Benefit
Dalteparin
Fragmin® · LMWH
Prophylactic dose
5,000 IU SC once daily
Treatment dose
100 IU/kg SC BD or 200 IU/kg SC OD (max 18,000 IU)
Cancer-associated VTE
200 IU/kg SC OD × 1 month → 150 IU/kg OD (CLOT trial regimen)
Renal adjustment
Anti-Xa monitoring if CrCl <30 mL/min; dose reduction considered
PBS status
✔ PBS General Benefit
UFH Dosing & Monitoring
UFH for treatment of VTE: initial bolus 80 IU/kg IV (max 5,000 IU), followed by infusion 18 IU/kg/hour (max 1,560 IU/hour). Adjust per institution nomogram targeting aPTT 1.5–2.5× control (typically 60–85 seconds, assay-dependent). Anti-Xa levels (target 0.3–0.7 IU/mL) are preferred in pregnancy and lupus anticoagulant–positive patients where aPTT is unreliable.
Unfractionated Heparin (UFH)
Heparin sodium injection · Multiple brands
Adult treatment
Bolus 80 IU/kg IV → infusion 18 IU/kg/hr; adjust to aPTT
Prophylactic
5,000 IU SC BD or TDS
Monitoring
aPTT 6 hrs post-bolus, then 6-hourly until stable, then daily
PBS status
✔ PBS General Benefit
Reversal — Protamine Sulfate
Protamine Sulfate
Heparin neutraliser
UFH reversal
1 mg protamine per 100 IU UFH given in prior 2–3 hours IV (max 50 mg); infuse slowly ≤5 mg/min
LMWH reversal
1 mg protamine per 1 mg enoxaparin (if given <8 hrs ago); 0.5 mg per 1 mg (if 8–12 hrs). Only ~60% effective.
Caution
Anaphylaxis risk — especially in fish-allergy (historically, though now synthetic) and prior protamine exposure. Give slowly with resuscitation equipment available.
PBS status
✔ PBS General Benefit
Heparin-Induced Thrombocytopenia (HIT)
HIT Type II (immune-mediated): Life-threatening prothrombotic complication occurring in 0.1–5% of heparin-exposed patients. Presents 5–14 days after heparin initiation (or earlier if prior exposure within 100 days). Characterised by >50% platelet fall, venous or arterial thrombosis. Immediately cease ALL heparin (including flushes) and commence an alternative anticoagulant (argatroban in Australia). Do NOT transfuse platelets. Calculate 4T score before testing.
| 4T Score Criterion | 0 Points | 1 Point | 2 Points |
|---|---|---|---|
| Thrombocytopenia | <30% fall or <10 × 10⁹/L | 30–50% fall or 10–19 × 10⁹/L | >50% fall and ≥20 × 10⁹/L |
| Timing | <4 days without recent exposure | Day 5–10 or ≤1 day if exposure 30–100 days ago | Day 5–10 (clear) or ≤1 day (recent exposure) |
| Thrombosis | None | Progressive/recurrent thrombosis; skin necrosis | Confirmed thrombosis or necrosis |
| Other causes | Definite alternative | Possible alternative | None apparent |
Interpretation: Score 0–3: low probability (HIT unlikely); 4–5: intermediate (test for HIT antibodies — PF4/heparin ELISA and serotonin release assay); 6–8: high probability (cease heparin, start alternative anticoagulant immediately pending results).
Argatroban
Direct thrombin inhibitor — HIT alternative
Adult dose
2 µg/kg/min IV infusion (no bolus); adjust to aPTT 1.5–3× baseline. Reduce to 0.5 µg/kg/min in hepatic impairment.
Half-life
~40–50 minutes
PBS status
⚠ PBS Authority Required
Direct Oral Anticoagulants (DOACs) & Reversal Agents
Overview & Advantages
DOACs represent a paradigm shift in anticoagulation, offering fixed dosing, predictable pharmacokinetics, fewer drug interactions, and no routine laboratory monitoring. Four DOACs are PBS-listed in Australia: apixaban, rivaroxaban, edoxaban (factor Xa inhibitors), and dabigatran (direct thrombin inhibitor).
When DOACs are NOT appropriate: Mechanical heart valves (RE-ALIGN trial — excess thrombosis/bleeding with dabigatran), antiphospholipid syndrome (TRAPS trial — excess events with rivaroxaban in triple-positive APS), severe hepatic impairment (Child–Pugh C), and pregnancy/lactation.
DOAC Pharmacology Comparison
| Feature | Apixaban | Rivaroxaban | Edoxaban | Dabigatran |
|---|---|---|---|---|
| Target | Factor Xa | Factor Xa | Factor Xa | Factor IIa (thrombin) |
| Prodrug | No | No | No | Yes (dabigatran etexilate) |
| Bioavailability | ~50% | ~80% (with food) | ~62% | ~6.5% |
| t½ (normal renal) | ~12 hours | ~5–9 hours (young); 11–13 hrs (elderly) | ~10–14 hours | ~12–17 hours |
| Renal clearance | ~27% | ~33% (active drug); 66% total | ~50% | ~80% |
| Food effect | Minimal | Take with food (↑ absorption 39%) | Minimal | Minimal |
| CYP metabolism | CYP3A4 (minor) | CYP3A4/2J2 (major) | Minimal CYP | None (ester hydrolysis) |
| P-gp substrate | Yes | Yes | Yes | Yes (major) |
| Dialysable | No | No | No | Yes (~60% in 2–3 hrs) |
Australian Indications (PBS-listed)
| Indication | Apixaban | Rivaroxaban | Edoxaban | Dabigatran |
|---|---|---|---|---|
| Non-valvular AF | ✔ | ✔ | ✔ | ✔ |
| VTE treatment | ✔ | ✔ | ✔ | ✔ |
| VTE prophylaxis (hip/knee) | ✔ (hip only) | ✔ (hip & knee) | ✘ | ✔ (hip & knee) |
| ACS (with antiplatelet) | ✘ | ✔ (2.5 mg BD + DAPT) | ✘ | ✘ |
| CAD/PAD | ✘ | ✔ (2.5 mg BD + ASA) | ✘ | ✘ |
Dosing — Atrial Fibrillation
Apixaban
Eliquis® · Factor Xa inhibitor
AF dose
5 mg PO BD
Reduce if
≥2 of: age ≥80, wt ≤60 kg, Creatinine ≥133 µmol/L → 2.5 mg BD
VTE treatment
10 mg PO BD × 7 days → 5 mg PO BD
Renal adjustment
CrCl ≥25 mL/min: no adjustment. CrCl 15–25: use with caution (limited data). CrCl <15: avoid.
PBS status
✔ PBS General Benefit
Rivaroxaban
Xarelto® · Factor Xa inhibitor
AF dose
20 mg PO OD with evening meal
Reduce if
CrCl 15–49 mL/min → 15 mg OD with food
VTE treatment
15 mg PO BD with food × 21 days → 20 mg OD with food
Renal adjustment
CrCl 15–49: 15 mg OD (AF). CrCl <15: avoid.
PBS status
✔ PBS General Benefit
Edoxaban
Lixiana® · Factor Xa inhibitor
AF dose
60 mg PO OD
Reduce if
CrCl 15–50 mL/min, wt ≤60 kg, or concomitant P-gp inhibitors (ciclosporin, dronedarone, erythromycin) → 30 mg OD
VTE treatment
60 mg OD (after initial ≥5 days parenteral anticoagulation). 30 mg OD if reduced-dose criteria met.
Renal adjustment
CrCl 15–50: 30 mg OD. CrCl <15: avoid. CrCl >95: avoid (Hokusai-VTE showed reduced efficacy)
PBS status
✔ PBS General Benefit
Dabigatran
Pradaxa® · Direct thrombin (IIa) inhibitor
AF dose
150 mg PO BD
Reduce if
Age ≥80, CrCl 30–50, concomitant verapamil, or HAS-BLED ≥3 → 110 mg BD
VTE treatment
150 mg PO BD (after initial parenteral anticoagulation ≥5 days)
Renal adjustment
CrCl 30–50: 110 mg BD (consider). CrCl <30: contraindicated.
Capsule handling
Must be dispensed in original blister; do not decant (moisture-sensitive). Use within 4 months of opening bottle.
PBS status
✔ PBS General Benefit
Critical dosing safety — DOAC dose reduction: Evidence-based dose reduction criteria must be strictly applied. Under-dosing (e.g., prescribing apixaban 2.5 mg BD when only 1 of 3 criteria met) is associated with increased stroke risk with no reduction in bleeding (US AFib Optimal Treatment trial, MAJIC trial). Never reduce dose solely based on age, weight, or creatinine alone for apixaban — at least 2 of 3 criteria must be met.
Key Drug Interactions
| Interaction | Affected DOACs | Management |
|---|---|---|
| Strong CYP3A4 + P-gp inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) | Apixaban, rivaroxaban | Avoid combination or reduce dose |
| Strong CYP3A4 + P-gp inducers (rifampicin, carbamazepine, phenytoin, St John's wort) | All DOACs | Avoid — significantly reduces DOAC levels |
| P-gp inhibitors (amiodarone, verapamil, dronedarone, ciclosporin, ticagrelor) | Dabigatran (major), edoxaban | Dose reduction (dabigatran 110 mg BD with verapamil); caution with others |
| Dual antiplatelet therapy | All | Increased bleeding risk; minimise triple therapy duration (see AF + ACS guidance) |
| NSAIDs | All | Avoid if possible; increased GI bleeding risk |
Laboratory Assessment of DOAC Effect
DOACs do not require routine monitoring. However, laboratory assessment may be necessary in specific clinical scenarios:
| DOAC | Preferred Assay | Routine Coagulation | Clinical Scenarios for Testing |
|---|---|---|---|
| Apixaban, Rivaroxaban, Edoxaban | Calibrated anti-Xa assay | PT: mildly prolonged (rivaroxaban most). aPTT: insensitive. | Acute bleeding, emergency surgery, extremes of weight, renal impairment, suspected non-adherence, overdose |
| Dabigatran | dTT (dilute thrombin time) or ECT | aPTT: prolonged (non-linear). TT: very prolonged/saturating (qualitative, not quantitative). | As above; also to confirm absence of drug prior to surgery |
Perioperative management: Stop DOACs 1–2 days before low-bleeding-risk surgery (1 day if CrCl >60; 2 days if CrCl 30–60). Stop 3 days before high-bleeding-risk surgery. Dabigatran requires an extra day if CrCl 30–50 mL/min. No bridging with heparin required in most cases. Check anti-Xa or dTT if timing uncertainty.
DOAC Reversal Strategies
Minor Bleeding
Supportive Measures
Withhold next dose. Apply local haemostatic measures. DOACs have short half-lives — time is often the best reversal agent. If last dose <2–4 hours ago, consider oral activated charcoal 50 g (if airway protected).
Setting: Observation / Ward
Moderate Bleeding
Non-Specific Reversal
4-factor PCC (Octaplex®) 25–50 IU/kg IV. Tranexamic acid 1 g IV. Supportive measures (fluid resuscitation, transfusion). If dabigatran: consider haemodialysis if CrCl permits.
Setting: ED / Hospital
Life-Threatening
Specific Reversal Agents
Dabigatran: Idarucizumab (Praxbind®) 5 g IV (2 × 2.5 g boluses). Apixaban/Rivaroxaban: Andexanet alfa (Ondexxya®) bolus + infusion. Also add PCC and tranexamic acid.
Setting: ICU / ED Resuscitation
Specific Reversal Agents — Detail
Idarucizumab
Praxbind® · Humanised monoclonal antibody fragment (Fab)
Indication
Reversal of dabigatran for emergency surgery or life-threatening/uncontrolled bleeding
Dose
5 g IV as two consecutive 2.5 g/50 mL infusions (or bolus injections over ~5 min each)
Onset
Immediate — complete dabigatran neutralisation within minutes
Duration
May re-accumulate dabigatran from tissue depot after ~24 hours; consider repeat dosing if re-bleeding
Renal adjustment
None — binds dabigatran directly, does not rely on renal clearance of drug
PBS status
✔ PBS Authority Required (Specialist only)
Andexanet Alfa
Ondexxya® · Recombinant modified Factor Xa decoy protein
Indication
Reversal of apixaban or rivaroxaban for life-threatening/uncontrolled bleeding
Dose (low dose)
If last DOAC dose >8 hrs or ≤10 mg apixaban / ≤10 mg rivaroxaban: bolus 400 mg IV at ~30 mg/min → infusion 480 mg over 120 min (4 mg/min)
Dose (high dose)
If last DOAC dose ≤8 hrs and >10 mg apixaban or >10 mg rivaroxaban: bolus 800 mg IV at ~30 mg/min → infusion 960 mg over 120 min (8 mg/min)
Onset
Anti-Xa activity reduced by ~90% within minutes of bolus
Caution
Thrombotic risk — ANNEXA-4 trial reported 10% thrombotic events. Resume therapeutic anticoagulation as soon as medically appropriate.
PBS status
✔ PBS Authority Required (Specialist only)
Reversal pearls: Idarucizumab is highly effective, well-tolerated, and works within minutes — it should be stocked in all emergency departments. Andexanet alfa is expensive (~,000 per dose in Australia) and has limited availability; coordinate with haematology. PCC remains an acceptable alternative for Xa inhibitor reversal when andexanet is unavailable, and is always appropriate as adjunctive therapy.
Monitoring
Monitoring by Anticoagulant Class
| Agent | Routine Monitoring | Laboratory Test | Special Monitoring |
|---|---|---|---|
| Warfarin | Required — INR every 4 weeks | PT/INR (target 2.0–3.0) | LFTs at baseline; FBC for occult bleeding |
| UFH | Required — aPTT or anti-Xa | aPTT 1.5–2.5× control (or anti-Xa 0.3–0.7 IU/mL) | FBC (platelets) every 2–3 days for HIT surveillance |
| LMWH | Not routine | Anti-Xa (peak 4 hrs post-dose; target 0.5–1.0 IU/mL BD, 1.0–2.0 IU/mL OD) | Renal function, anti-Xa in obesity, pregnancy, CrCl <30 |
| DOACs | Not required | Calibrated anti-Xa (Xa inhibitors) or dTT/ECT (dabigatran) | Renal function every 6–12 months (more often if CrCl <60). FBC annually. LFTs at baseline. |
Renal Function Monitoring for DOACs
- CrCl ≥60 mL/min: Monitor annually.
- CrCl 30–59 mL/min: Monitor every 6 months.
- CrCl 15–29 mL/min: Monitor every 3 months (dabigatran contraindicated; Xa inhibitors — limited data, specialist oversight recommended).
- Use Cockcroft–Gault equation (not CKD-EPI) for DOAC dosing decisions, as trial data were based on Cockcroft–Gault–derived CrCl.
MBS Items Relevant to Anticoagulant Monitoring
MBS
INR (Prothrombin Time)
Item 65111 — Medicare-rebated for warfarin monitoring in community pathology. Point-of-care INR (CoaguChek®) funded under MBS item for warfarin-treated patients.
MBS
aPTT
Item 65112 — Available in all hospital and community pathology. Standard for UFH monitoring.
Specialist
Anti-Xa Assay (Calibrated)
Not universally available. Mainly in tertiary hospital laboratories. Request with clinical indication (LMWH monitoring, DOAC level assessment). Not MBS-rebated for DOAC levels.
Specialist
Dilute Thrombin Time (dTT) / Ecarin Clotting Time (ECT)
Tertiary laboratory only. For dabigatran quantification. Not MBS-rebated.
MBS
Full Blood Count
Item 65070/65090 — Essential for detecting anticoagulant-related bleeding (Hb drop, platelet monitoring for HIT).
MBS
Serum Creatinine / eGFR
Item 66500 — Required at baseline and periodically for DOAC dose adjustment. Use Cockcroft–Gault CrCl for DOAC dosing.
Special Populations
Pregnancy
Warfarin
Teratogenic (warfarin embryopathy) in first trimester. Contraindicated in pregnancy except mechanical heart valves where benefit outweighs risk (shared decision, specialist).
Heparin (LMWH preferred)
Drug of choice in pregnancy. Enoxaparin does not cross the placenta. Dose adjustment with weight gain; anti-Xa monitoring recommended. UFH used peri-partum for epidural timing.
DOACs
Contraindicated in pregnancy and breastfeeding. Animal studies show reproductive toxicity. Switch to LMWH before conception or immediately upon confirmed pregnancy.
Paediatrics
Warfarin
Used for mechanical heart valves and some complex congenital heart disease. Dosing: 0.1–0.2 mg/kg/day. INR monitoring is challenging; involves specialist paediatric haematology/cardiology. Vitamin K–restricted diet impractical in infants.
LMWH
First-line for most paediatric anticoagulation. Enoxaparin 1.5 mg/kg/12h (neonates <2 months); 1 mg/kg/12h (≥2 months). Anti-Xa monitoring essential due to variable pharmacokinetics.
DOACs
Not TGA-approved in children <18 years (dabigatran approved for adolescents ≥15 years in some indications in Europe — not Australia). Ongoing trials (EINSTEIN-Jr for rivaroxaban).
Elderly (≥75 years)
Warfarin
Start at 2–3 mg. Higher bleeding risk. Time in therapeutic range (TTR) often poor. Consider supervised INR monitoring or POC testing.
DOACs
Generally preferred over warfarin in elderly (lower ICH risk). Apixaban: favourable bleeding profile (ARISTOTLE). Dabigatran 110 mg BD for age ≥80 years. Renal monitoring critical as CrCl declines with age.
Fall risk
Frequent falls are not a contraindication to anticoagulation. Modelling suggests a patient would need >295 falls/year for anticoagulation risk to outweigh AF stroke prevention benefit (Man-Son-Hing et al.).
Renal Impairment
CrCl 30–50 mL/min
DOACs: dose reductions apply (see dosing tables). LMWH: reduce enoxaparin to OD dosing; consider anti-Xa monitoring. Warfarin: no dose change but monitor more frequently.
CrCl <30 mL/min
Dabigatran: contraindicated. Xa inhibitors: limited data; use with extreme caution or avoid. UFH preferred if heparin required. Warfarin may be preferred in severe CKD/dialysis.
Dialysis
UFH is standard for haemodialysis. Warfarin for AF if dialysis-dependent (no DOAC trial evidence in dialysis population). DOACs not recommended.
Hepatic Impairment
Child–Pugh A
DOACs: use with caution. Apixaban and rivaroxaban — limited data but pharmacokinetics only modestly affected.
Child–Pugh B
Rivaroxaban: avoid (reduced metabolism). Apixaban: use with caution. Dabigatran: avoid. Warfarin: unpredictable response; increased sensitivity.
Child–Pugh C
All DOACs: contraindicated (coagulopathy, impaired synthesis of clotting factors). Warfarin: unpredictable; avoid if possible.
Obesity (BMI >40 kg/m² or wt >120 kg)
LMWH
Weight-based dosing. Enoxaparin: 1 mg/kg SC BD (max single dose 150 mg) or consider 0.5 mg/kg SC BD if >150 kg. Anti-Xa monitoring recommended.
DOACs
Limited data above BMI 40 or weight >120 kg. ISTH and ESC position statements suggest apixaban and rivaroxaban may be used but anti-Xa levels should be checked. If concerned, consider warfarin.
Bariatric surgery
Post-bariatric surgery may affect DOAC absorption (particularly malabsorptive procedures). Monitor clinically; consider anti-Xa levels.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
Aboriginal and Torres Strait Islander Australians experience a higher burden of conditions requiring anticoagulation, including atrial fibrillation, venous thromboembolism, rheumatic heart disease, and cardiovascular disease, often at younger ages and with greater comorbidity than non-Indigenous Australians. Despite this, anticoagulant utilisation rates remain lower, and outcomes are poorer.
Rheumatic heart disease (RHD): RHD remains a significant health burden for Aboriginal and Torres Strait Islander peoples, particularly in Northern Australia. Secondary prophylaxis with penicillin and anticoagulation with warfarin for mechanical valves or AF is critical. RHDAustralia (www.rhdaustralia.org.au) provides specific clinical guidelines and register management.
📚 References
- 1. National Blood Authority Australia. Australian Patient Blood Management Guidelines — Module 2: Perioperative. Canberra: NBA; 2012 (updated 2022).
- 2. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–1201.
- 3. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). N Engl J Med. 2011;365(11):981–992.
- 4. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF). N Engl J Med. 2011;365(10):883–891.
- 5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). N Engl J Med. 2009;361(12):1139–1151.
- 6. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal — full cohort analysis (RE-VERSE AD). N Engl J Med. 2017;377(5):431–441.
- 7. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors (ANNEXA-4). N Engl J Med. 2019;380(14):1326–1335.
- 8. RACGP. Guidelines for preventive activities in general practice (Red Book), 10th edn. Melbourne: RACGP; 2024.
- 9. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards, 2nd edn. Sydney: ACSQHC; 2021.
- 10. Australian Institute of Health and Welfare (AIHW). Atrial fibrillation in Australia. Cat. no. CVD 90. Canberra: AIHW; 2024.
- 11. RHDAustralia. The Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease, 3rd edn. Darwin: Menzies School of Health Research; 2020.
- 12. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373–498.
- 13. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543–603.
- 14. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest. 2004;126(3 Suppl):311S–337S.
- 15. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677–685.